Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration
Kaiqin She, Jing Su, Qingnan Wang, Yi Liu, Xiaomei Zhong, Xiu Jin, Qinyu Zhao, Jianlu Xiao, Ruiting Li, Hongxin Deng, Fang Lü, Yang Yang, Yuquan Wei
Abstract
genome copies of AAV8-nVEGFi exhibited a significantly increased reduction in the CNV area compared with AAV8-aflibercept (78.1% vs. 63.9%, p < 0.05), while causing no structural or functional changes to the retina. In conclusion, this preclinical study showed that subretinal injection of AAV8-nVEGFi was long lasting, well tolerated, and effective for nAMD treatment, supporting future translation to the clinic.
Topics & Concepts
Macular degenerationMedicineDegeneration (medical)OphthalmologyChoroidal neovascularizationRetinal Diseases and TreatmentsRetinal Development and DisordersRetinal and Optic Conditions